Ixogel®: Agreement on Special Protocol Assessment (SPA) by the US Food and Drug Administration for the Prevention of Lyme Disease
Ixodes AG, a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention of Lyme Disease, today announced that the company has reached agreement with the US Food and Drug Administration (FDA) on the phase III protocol according to the Special Protocol... - March 01, 2016
Ixogel® is Granted QIDP Status by the US Food and Drug Administration
Ixodes AG, a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention of Lyme Disease, today announced that the U.S. Food and Drug Administration (FDA) has designated the company's lead product candidate, Ixogel®, as a Qualified Infectious Disease Product (QIDP) for the prevention of Lyme Disease after a tick bite and is working with the company on the phase III protocol. Special Protocol Assessment (SPA) confirmation expected soon. - September 29, 2015